We are live on
!
Find out more
HP
HealthInvest Partners Portfolio holdings
AUM
$372M
1-Year Est. Return
59.89%
This Fund
S&P 500
This Quarter
Est. Return
-3.08%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$214M
AUM Growth
+$1.1M
(+0.52%)
Cap. Flow
+$16.7M
Cap. Flow
% of AUM
7.81%
Top 10 Holdings %
Top 10 Hldgs %
77.57%
Holding
21
New
7
Increased
5
Reduced
6
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bausch Health
BHC
|
+$27.4M |
| 2 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$13.4M |
| 3 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
+$13.4M |
| 4 |
Merck
MRK
|
+$12.9M |
| 5 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$5.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$23.2M |
| 2 |
MGLN
Magellan Health Services, Inc.
MGLN
|
+$15.3M |
| 3 |
VAR
Varian Medical Systems, Inc.
VAR
|
+$14.9M |
| 4 |
GNC
GNC Holdings, Inc.
GNC
|
+$6.71M |
| 5 |
LPNT
LifePoint Health, Inc.
LPNT
|
+$6.61M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.85% |
| 2 | Industrials | 8.73% |
| 3 | Financials | 5.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Anika Therapeutics
ANIK
$258M
| $21.9M | 10.27% |
490,331
+111,586
| +29% | +$4.53M |
|
|
FEIC
2
DELISTED
FEI COMPANY
FEIC
| $21.3M | 9.99% |
239,609
+60,846
| +34% | +$4.71M |
|
|
LPNT
3
DELISTED
LifePoint Health, Inc.
LPNT
| $19M | 8.9% |
274,430
-99,000
| -27% | -$6.61M |
|
|
GNC
4
DELISTED
GNC Holdings, Inc.
GNC
| $18.6M | 8.73% |
586,955
-234,235
| -29% | -$6.71M |
|
|
AMAG
5
DELISTED
AMAG Pharmaceuticals
AMAG
| $17.3M | 8.11% |
740,585
+220,585
| +42% | +$5.24M |
|
6
Supernus Pharmaceuticals
SUPN
$2.59B
| $13.8M | 6.45% |
903,533
-147,744
| -14% | -$1.93M |
|
7
Charles River Laboratories
CRL
$11.2B
| $13.5M | 6.34% |
178,307
-4,400
| -2% | -$326K |
|
|
TARO
8
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $13.5M | 6.31% |
+94,005
| New | +$13.4M |
|
|
SYNH
9
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $13.4M | 6.26% |
+324,270
| New | +$13.4M |
|
|
10
Merck
MRK
$322B
| $13.3M | 6.23% |
+263,467
| New | +$12.9M |
|
11
Elevance Health
ELV
$81.5B
| $13.1M | 6.11% |
93,900
-11,800
| -11% | -$1.58M |
|
|
GTS
12
DELISTED
Triple-S Management Corporation
GTS
| $12.5M | 5.86% |
529,575
-108,388
| -17% | -$2.43M |
|
|
13
Bausch Health
BHC
$2.58B
| $9.73M | 4.56% |
+370,000
| New | +$27.4M |
|
|
SSRG
14
DELISTED
SYMMETRY SURGICAL INC COMMON STK
SSRG
| $3.12M | 1.46% |
316,427
+18,000
| +6% | +$169K |
|
15
OraSure Technologies
OSUR
$279M
| $2.93M | 1.37% |
+405,771
| New | +$2.58M |
|
|
ASRT
16
DELISTED
Assertio
ASRT
| $2.79M | 1.3% |
+3,333
| New | +$3.09M |
|
|
SCLN
17
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
| $2.6M | 1.22% |
+236,288
| New | +$2.1M |
|
18
ImmuCell
ICCC
$101M
| $1.15M | 0.54% |
168,323
+43,031
| +34% | +$287K |
|
|
19
Gilead Sciences
GILD
$162B
| – | – |
-229,300
| Closed | -$23.2M |
|
|
MGLN
20
DELISTED
Magellan Health Services, Inc.
MGLN
| – | – |
-248,934
| Closed | -$15.3M |
|
|
VAR
21
DELISTED
Varian Medical Systems, Inc.
VAR
| – | – |
-209,830
| Closed | -$14.9M |
|
Similar funds
KP
AWA
TCM
SAAM
PAA
PC
BOCH
GIP
HealthInvest Partners's Q1 2016 Portfolio in Review
As of Q1 2016, HealthInvest Partners held 21 positions worth $214M, up 0.52% from $212M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
HealthInvest Partners deployed $16.7M of net new capital in Q1 2016, opening 7 new positions and adding to 5 existing holdings. Its largest new stake was Bausch Health: 370,000 shares worth $9.73M.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 59% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was GNC Holdings, Inc., an estimated $6.71M trimmed.
- HealthInvest Partners's largest Q1 2016 buy was Bausch Health: 370,000 shares worth $9.73M.
- HealthInvest Partners added most to AMAG Pharmaceuticals in Q1 2016, an estimated $5.24M increase.
- HealthInvest Partners's biggest Q1 2016 reduction was GNC Holdings, Inc., cutting an estimated $6.71M.
- HealthInvest Partners fully exited Gilead Sciences in Q1 2016, selling an estimated $23.2M.
- HealthInvest Partners's ten largest holdings make up 78% of its $214M portfolio in Q1 2016.
- HealthInvest Partners opened 7 new positions and closed 3 in Q1 2016.
- HealthInvest Partners's portfolio value rose 0.52% quarter-over-quarter to $214M.
Based on HealthInvest Partners's 13F filing for Q1 2016, filed 19 Apr 2016.